Design and Synthesis of 3,7-diarylimidazopyridines As Inhibitors of the VEGF-receptor KDR

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2004 Mar 12

PMID 15012992

Citations 9

Authors

Zhicai Wu

Mark E Fraley

Mark T Bilodeau

Mildred L Kaufman

Edward S Tasber

Adrienne E Balitza

George D Hartman

Kathleen E Coll

Keith Rickert

Jennifer Shipman

Bin Shi

Laura Sepp-Lorenzino

Kenneth A Thomas

Affiliations

Soon will be listed here.

Abstract

3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.

Citing Articles

studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations.

Jiang Y, Yang W, Wang F, Zhou B RSC Adv. 2023; 13(22):14808-14824.

PMID: 37197188 PMC: 10184002. DOI: 10.1039/d3ra01316b.

Superparamagnetic nanoparticle-catalyzed coupling of 2-amino pyridines/pyrimidines with -chalcones.

Nguyen O, Ha P, Dang H, Vo Y, Nguyen T, Le N RSC Adv. 2022; 9(10):5501-5511.

PMID: 35515937 PMC: 9060791. DOI: 10.1039/c9ra00097f.

SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2.

Choi H, Kim M, Lee K, Min Lee K, Choi Y, Shin Y Oncotarget. 2016; 7(22):32969-79.

PMID: 27105528 PMC: 5078067. DOI: 10.18632/oncotarget.8808.

Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib.

Ebadi A, Razzaghi-Asl N, Shahabipour S, Miri R Iran J Pharm Res. 2014; 13(2):405-15.

PMID: 25237336 PMC: 4157016.

Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

Frett B, Moccia M, Carlomagno F, Santoro M, Li H Eur J Med Chem. 2014; 86:714-23.

PMID: 25232968 PMC: 4666024. DOI: 10.1016/j.ejmech.2014.09.023.